Givaudan Active Beauty has launched Neoporyl, a biocatalytically derived active ingredient that is said to reduce the size of enlarged skin pores.
Neoporyl is based on a biomimetic source of energy and key amino acids. It counteracts the two key biological causes of ‘porexia’, as the enlargement of pore sizes is increasingly known: parakeratosis (an alteration of the epidermal structure) and dermis fragility.
Clinical tests cited by Givaudan have demonstrated a significant reduction of pore size in Caucasian women within two weeks for all volunteers, regardless of age range, and with increasing efficacy during the two-month trial period, down to -24% versus placebo. Similar benefits were perceived among Asian men, with a significant effect on pore size in one week, up to 2.4 times better than the placebo with an additional improvement of the skin appearance
“Our active ingredient is able to limit hyperdifferentiation in the epidermis, reduce nucleated cell density in the stratum corneum, restore collagen production in the fragile dermis, and boost mature collagen and decorin production,” said Mathias Fleury, head of the Actives category for Active Beauty.
